Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors alpha to stimulate hepatic apolipoprotein A-I secretion.
A uniquely formulated soy phospholipid, phosphatidylinositol (PI), is under development as a therapeutic agent for increasing plasma high-density lipoprotein (HDL) levels. Soy PI has been shown to increase plasma HDL and apolipoprotein A-I (apoA-I) levels in phase I human trials. Low micromolar concentrations of PI increase the secretion of apoA-I in model human hepatoma cell lines, through activation of G-protein and mitogen-activated protein (MAP) kinase pathways. Experiments were undertaken to determine the importance of the PI head group and acyl chain composition on hepatic apoA-I secretion. Phospholipids with choline and inositol head groups and one or more linoleic acid (LA) acyl chains were shown to stimulate apoA-I secretion by HepG2 cells and primary human hepatocytes. Phospholipids containing two LA groups (dilinoleoylphosphatidylcholine, DLPC) were twice as active as those with only one LA group and promoted a 4-fold stimulation in apoA-I secretion. Inhibition of cytosolic phospholipase A2 with pyrrolidine 1 (10 microM) resulted in complete attenuation of PI- and DLPC-induced apoA-I secretion. Pretreatment with the peroxisome proliferator-activated receptor alpha (PPARalpha) inhibitor MK886 (10 microM) also completely blocked PI- and DLPC-induced apoA-I secretion. Hepatic PPARalpha expression was significantly increased by both PI and DLPC. However, in contrast to that seen with the fibrate drugs, PI caused minimal inhibition of catalytic activities of cytochrome P450 and UGT1A1 enzymes. These data suggest that LA-enriched phospholipids stimulate hepatic apoA-I secretion through a MAP kinase stimulation of PPARalpha. LA-enriched phospholipids have a greater apoA-I secretory activity than the fibrate drugs and a reduced likelihood to interfere with concomitant drug therapies.
Pandey
Nihar R
NR
Liponex, Inc., 1740 Woodroffe Avenue, Ottawa, Ontario K2G 3R8, Canada.
Renwick
Joanna
J
Misquith
Ayesha
A
Sokoll
Ken
K
Sparks
Daniel L
DL
D016632:Apolipoprotein A-I / Q000378:metabolism*; D065607:Cytochrome P-450 Enzyme Inhibitors; D004797:Enzyme-Linked Immunosorbent Assay; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D019787:Linoleic Acid / Q000737:chemistry*; D008862:Microsomes, Liver / Q000187:drug effects* / Q000378:metabolism; D047493:PPAR alpha / Q000378:metabolism*; D064801:Phospholipase A2 Inhibitors; D010743:Phospholipids / Q000737:chemistry / Q000378:metabolism*; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism
D016632:Apolipoprotein A-I; D065607:Cytochrome P-450 Enzyme Inhibitors; D007328:Insulin; D047493:PPAR alpha; D064801:Phospholipase A2 Inhibitors; D010743:Phospholipids; D019787:Linoleic Acid; D051057:Proto-Oncogene Proteins c-akt; D005947:Glucose